Migraine, prevention

Calcitonin Gene-Related Peptide (CGRP) Antagonist.
Fremanezumab is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.

Distribution: Vd: ~6 L
Metabolism: Degraded by enzymatic proteolysis into small peptides and amino acids.
Half-life elimination: ~31 days
Time to peak: 5 to 7 days
Excretion: Clearance: 0.141 L/day

Serious hypersensitivity (eg, anaphylaxis, angioedema) to fremanezumab or any component of the formulation.

Fetal risk cannot be ruled out.

Infant risk cannot be ruled out.
Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when used during breastfeeding. Weigh the potential benefits of drug treatment against potential risks before prescribing this drug during breastfeeding.

Local: Injection site reaction

Migraine, prevention (alternative agent):
SUBQ: 225 mg monthly or 675 mg every 3 months

Store in the refrigerator at 2°C to 8°C